Home >Research Discovery>Discovery Biology
Introduction of group leader
Office phone: +82-31-8018-8210
Office location: R4.07
The Leishmania Research Laboratory focuses on discovery of novel inhibitors and drug targets against Leishmania infections. The research activities are focused on two key areas: 1) discovery of novel lead compounds in collaboration with screening and chemistry platforms offered at IPK, and 2) understanding the fundamental biology of Leishmania with a special emphasis on the host – Leishmania interaction. At the interface of these two approaches, we ultimately aim to understand the underlying mechanism of parasite pathogenesis as well as to deliver novel therapeutic interventions for Leishmania infections.
Based on our expertise of molecular parasitology, biochemistry and biophysics, we will approach the target system from the parasite or organelle level, as well as the atomic or molecular level.
Our present activity focuses on:
• Identifying hit compounds using intracellular Leishmania high contents/high throughput screening methods
• Hit to lead optimization of identified anti-leishmanial compounds
• Mode of action studies on generated lead compounds
• In-depth understanding of host-Leishmania interactions through cell-based screening and molecular parasitology approaches
Infectivity and Drug Susceptibility Profiling of Different Leishmania-Host Cell Combinations
Kyung-Hwa Baek, Laura Piel, Thibault Rosazza, Eric Prina, Gerald F. Späth, and Joo Hwan No
Pathogens. 2020 May; 9(5): 393
In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei
Trong-Nhat Phan, Kyung-Hwa Baek, Nakyung Lee, Soo Young Byun, David Shum, and Joo Hwan No
Molecules. 2020 Apr; 25(8): 1980
Evaluation of Parameters Impacting Drug Susceptibility in Intracellular Trypanosoma cruzi Assay Protocols. (Front Cover)
Yang G, Lee N, Ioset JR, No JH
SLAS Discov. 2017 Feb;22(2):125-134
Antileishmanial Mechanism of Diamidines Involves Targeting Kinetoplasts.
Yang G, Choi G, No JH
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6828-6836
In Vitro and in Vivo Activity of Multitarget Inhibitors against Trypanosoma brucei.
Yang G, Zhu W, Wang Y, Huang G, Byun S, Choi G, Li K, Huang Z, Docampo R, Oldfield E, No JH
ACS Infect Dis. 2015 Aug 14;1(8):388-98